
With the aid of $17 million in grant funding, UCSF Benioff Children’s Hospital Oakland will initiate a 4-year trial evaluating CRISPR/Cas9 gene editing as a potential cure for sickle cell disease.
Researchers at the institution have received a grant of $8.4 million from the California Institute for Regenerative Medicine and one of $8.6 million from the NIH Cure Sickle Cell Initiative, which NHLBI sponsors, to support the trial.
“It’s important to acknowledge that we got funding to do this clinical trial from the National Institutes of Health and the California Institute of